CVS Indication-Based Pricing For Cancer Drugs May Roll Out Later In 2016

Pharmacy benefit manager CVS is considering a range of drugs and indications for the program, noting some oncology approvals in the coming months may be eligible.

CVS Health Corp.’s pharmacy benefit manager unit is hoping to launch an indication-based pricing program for cancer drugs in the second half of 2016, according to CVS VP and Head of Specialty Client Solutions Surya Singh.

Singh discussed indication-based pricing – a novel contracting strategy in which payers and manufacturers settle on different prices for different...

More from United States

More from North America